Program
tenofovir amibufenamide
Also written as “HS-10234”, “Tenofovir Amibufenamide(TMF)” and “Tenofovir Amibufenamide(TMF)”.
Its studies are mostly in Hepatitis B, Chronic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 31 open or running | phase 4since Dec 13, 2024 | Mar 3, 2019 | none ahead |
| GNI Group | 10 open or running | phase 1since Dec 10, 2025 | Dec 10, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 3, 2019First study: phase 3 study in Chronic HBV InfectionNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT03903796 · 963 enrolled · China
- Jul 14, 2020Phase 1 study in Healthy SubjectsHansoh Pharmaceutical Group · NCT04477096 · 36 enrolled · China
- Dec 13, 2024Phase 4 study in Hepatitis B, ChronicHansoh Pharmaceutical Group · NCT06743438 · 640 enrolled · China
- Dec 10, 2025GNI Group’s first study: phase 1 study in Chronic Hepatitis B Liver FibrosisNew to GNI GroupGNI Group · NCT07295873 · 64 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07295873Chronic Hepatitis B Liver Fibrosis · China | 1 | Completed | GNI Group | May 29, 2026 | 64 |
| NCT06743438Hepatitis B, Chronic · China | 4 | Active, not recruiting | Hansoh Pharmaceutical Group | Jun 30, 2024 | 640 |
| NCT04477096Healthy Subjects · China | 1 | Completed | Hansoh Pharmaceutical Group | Sep 24, 2020 | 36 |
| NCT03903796Chronic HBV Infection · China | 3 | Completed | Hansoh Pharmaceutical Group | May 31, 2020 | 963 |
How it is read
Names in the registry
- “HS-10234”, 2 entries
- “Tenofovir Amibufenamide(TMF)”, 1 entry
- “Tenofovir Amibufenamide(TMF)”, 1 entry
Codes read as this program: HS10234.
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.